• successfully launched a number of new products during the year and post year-end, including key unlicensed- to-licensed product glycopyrronium bromide oral solution 1mg/5ml. (loss) earnings per share is calculated using the average number of shares in issue for each period: 2017: 134.8m; 2016: 125.0m; 2015: 54.5m. the division has a growing portfolio and pipeline of ul2l products, as well as complementary larger niche generic products across a number of therapeutic areas that the group aims to commercialise either independently or in partnership with other pharmaceutical businesses. some of the group’s difficulties this year are rooted in persevering with products where it has not been first to market. it would require substantial investment and time in advance of securing meaningful revenues for the group to build this capability. 5. uk-manufactured special in mhra-licensed facilities 8 quantum pharma plc annual report and accounts 2017 strategic report business model in-house development & regulatory expertise our positioning our business model uk secure & grow international developing distribution partnerships contracted relationships global sourcing capability established uk distribution network to pharmacies & hospitals visibility of specials market imported product licensed in (approved) country of origin uk-manufactured special in mhra-licensed facilities regulatory pathway uk-licensed medicine prescribing hierarchy choice/ risk specials division niche division preferred / lower less preferred/greater 9 quantum pharma plc annual report and accounts 2017 strategic report specials established and market-leading the specials division, which includes quantum pharmaceutical limited (‘qpl ’) and ul medicines limited (‘ulm’), occupies a market-leading position that provides the group with insight into prescribing trends across a large swathe of the specials market. the specials division’s reputation for reliability and quality has helped it to build long-term relationships with several key customers that are underpinned by exclusive supply contracts. our focus on the two core pillars of specials and niche will continue to drive performance improvement. broadening our commercial partnerships our non-ul2l portfolio is comprised of niche generic products where, although we will not have first-mover advantage and significant sales and marketing capability will likely be required to market them, we believe there remains a market opportunity. 2017 niche portfolio breakdown 57 total products 1 “we are well-placed to deliver future growth by focusing on our core niche and specials businesses.” in development/licensing process product licence received, awaiting launch launched or out-licensed 1 the portfolio breakdown defines individual products as those which vary with respect to their active pharmaceutical ingredient, strength, form or branding. the business has also continued to generate strong development, supply and royalty revenue from a range of third-party projects. qpl was also successful in retaining all major key accounts during the year, including securing a five-year exclusive supply relationship with our largest customer, aah pharmaceuticals limited, which supplies over 1,800 lloyds pharmacy stores and 8,000 independents 13 quantum pharma plc annual report and accounts 2017 strategic report across the uk. we exited the financial year with a much improved profitability run-rate that is supportive of market expectations for the current financial year and we are well-placed to deliver future growth by focusing on our core niche and specials businesses. it operates in a challenging market that is subject to regulated pricing across some of the division’s product range. this revised strategy has been implemented successfully resulting in a number of important contracts with large pharmaceutical companies and nhs trusts being secured during the financial year. the loss after tax from continuing operations includes non-cash charges relating to depreciation, amortisation and impairment of £12.9m (2016: £1.6m). all adjustments made to adjusted ebitda as set out in the definition above are net of tax where applicable. the group is also looking to partner with other businesses who have experience of commercialising non-ul2l products, where maximising their potential typically requires more time, investment and marketing expertise. • discontinued unprofitable product lines within the niche pharmaceuticals division, allowing management to focus on those offering best opportunities for growth. • renewal of exclusive contractual relationship with aah pharmaceuticals limited, the group’s largest specials customer, for a further five years. (loss) earnings per share from continuing operations is calculated using the average number of shares in issue for each period. there are risks that these key customer relationships could come to an end for a variety of commercial reasons, which would adversely impact group revenues. the group operates under a robust and compliant quality management system that is verified by regulators through frequent routine compliance inspections. the group works hard to develop and maintain close, co-operative relationships with inspectors at a number of levels within their respective organisations. risk trend increasing unchanged decreasing 23 quantum pharma plc annual report and accounts 2017 strategic report risk impact mitigation movement marketing authorisations (‘product licences’) for new products success in the group’s product development and licensing business is dependent on achieving licensed status for products in the pipeline. there is a risk that revenue and profit could be impacted should any of the group’s facilities become damaged. similarly, as an aim company, quantum pharma plc is not required to prepare or publish a report on directors’ remuneration. both of these companies experienced considerable growth and change during the periods that gerard served on their respective boards. as a corporate lawyer by background with more than 15 years’ experience in private practice he oversees and is responsible for the group legal function. his appointment will further strengthen the positive relationships he has developed with all of lamda’s suppliers and clients. the non-executive directors’ focus, in particular, on ensuring that strategic matters are carefully assessed and implemented. 4. ian johnson, dr john brown and christopher mills were each appointed to the board on 19 october 2016. fees for non-executive directors are determined by the board to recognise their time commitment and contribution. 3 chris rigg was appointed permanent ceo on 19 october 2016, but also continued in his role as cfo until 23 january 2017. 4 christopher mills and dr john brown were both appointed to the board on 19 october 2016. their fees are £40,000 per annum each. nick plumb senior statutory auditor for and on behalf of kpmg llp, statutory auditor chartered accountants quayside house 110 quayside newcastle upon tyne ne1 3dx 2 may 2017 46 quantum pharma plc annual report and accounts 2017 financial statements consolidated income statement for year ended 31 january 2017 note 2017 £000 2016 £000 continuing operations revenue 1,3 88,770 69,227 cost of sales (62,846) (43,352) gross profit 25,924 25,875 other operating income 4 16 204 distribution expenses (2,600) (2,571) administrative expenses (33,186) (16,019) operating (loss) profit 5,6,7 (9,846) 7,489 financial expense 8 (1,150) (902) net financing expense (1,150) (902) share of profit of equity-accounted investees, net of tax 15 145 106 (loss) profit before tax (10,851) 6,693 taxation 11 1,790 (780) (loss) profit for the year from continuing operations (9,061) 5,913 discontinued operations loss for the year from discontinued operations 9 (13,705) (317) (loss) profit for the year (22,766) 5,596 basic and diluted earnings per share attributed to equity shareholders of the company basic (p) 10 (16.9) 4.5 diluted (p) 10 (16.9) 4.3 basic (p) – continuing operations only 10 (6.7) 4.7 diluted (p) – continuing operations only 10 (6.7) 4.5 basic (p) – discontinued operations only 10 (10.2) (0.2) diluted (p) – discontinued operations only 10 (10.2) (0.2) consolidated statement of comprehensive income for year ended 31 january 2017 2017 £000 2016 £000 (loss) profit for the year (22,766) 5,596 other comprehensive income items that are or may be recycled subsequently into profit or loss foreign exchange translation differences 74 (3) other comprehensive income (loss) for the year, net of income tax 74 (3) total comprehensive (loss) income for the year (22,692) 5,593 attributable to: equity holders of the parent (22,692) 5,593 47 quantum pharma plc annual report and accounts 2017 financial statements consolidated balance sheet at 31 january 2017 note 2017 £000 2016 £000 non-current assets property, plant and equipment 13 4,211 5,967 intangible assets 14 59,493 78,432 investments 15 – 105 63,704 84,504 current assets inventories 17 3,985 4,887 tax receivable 228 307 trade and other receivables 18 14,965 13,410 cash and cash equivalents 19 7,941 4,240 27,119 22,844 total assets 90,823 107,348 current liabilities other interest-bearing loans and borrowings 20 (2,880) (7,880) trade and other payables 21 (22,433) (18,943) provisions 24 (572) (1,355) (25,885) (28,178) non-current liabilities other interest-bearing loans and borrowings 20 (18,080) (20,959) other payables 21 – (19) provisions 24 – (439) deferred tax liabilities 25 (244) (2,244) (18,324) (23,661) total liabilities (44,209) (51,839) net assets 3 46,614 55,509 equity attributable to equity holders of the parent share capital 26 16,912 12,500 share premium 27 74,799 64,940 consolidation reserve 27 (9,752) (9,752) translation reserve 27 116 42 other reserve 27 (21,726) (21,726) esop own share reserve 27 (484) (484) merger reserve 27 8,742 8,742 retained earnings 27 (21,993) 1,247 total equity 46,614 55,509 these financial statements were approved by the board of directors on 2 may 2017 and were signed on its behalf by: gt murray director company registered number: 09269818 48 quantum pharma plc annual report and accounts 2017 financial statements consolidated statement of changes in equity share capital £000 share premium £000 consolidation reserve £000 translation reserve £000 other reserve £000 esop own share reserve £000 merger reserve £000 retained earnings £000 total equity £000 balance at 1 february 2016 12,500 64,940 (9,752) 42 (21,726) (484) 8,742 1,247 55,509 total comprehensive income for the year loss for the year – – – – – – – (22,766) (22,766) other comprehensive income – – – 74 – – – – 74 total comprehensive income for the year – – – 74 – – – (22,766) (22,692) transactions with owners, recorded directly in equity issue of ordinary shares 4,412 10,588 – – – – – – 15,000 issue costs charged against share premium – (729) – – – – – – (729) contributions by and distributions to owners – – – – – – – (1,250) (1,250) equity-settled share based payment transactions – – – – – – – 776 776 total contributions by and distributions to owners 4,412 9,859 – – – – – (474) 13,797 total transactions with owners 4,412 9,859 – – – – – (474) 13,797 balance at 31 january 2017 16,912 74,799 (9,752) 116 (21,726) (484) 8,742 (21,993) 46,614 share capital £000 share premium £000 consolidation reserve £000 translation reserve £000 other reserve £000 esop own share reserve £000 merger reserve £000 retained earnings £000 total equity £000 balance at 1 february 2015 12,500 64,940 (9,752) 45 (21,726) (484) 8,742 (3,545) 50,720 total comprehensive income for the year profit for the year – – – – – – – 5,596 5,596 other comprehensive loss – – – (3) – – – – (3) total comprehensive income for the year – – – (3) – – – 5,596 5,593 transactions with owners, recorded directly in equity contributions by and distributions to owners – – – – – – – (937) (937) equity-settled share based payment transactions – – – – – – – 133 133 total contributions by and distributions to owners – – – – – – – (804) (804) total transactions with owners – – – – – – – (804) (804) balance at 31 january 2016 12,500 64,940 (9,752) 42 (21,726) (484) 8,742 1,247 55,509 49 quantum pharma plc annual report and accounts 2017 financial statements consolidated cash flow statement for year ended 31 january 2017 note 2017 £000 2016 £000 cash flows from operating activities (loss) profit for the year from continuing operations (9,061) 5,913 adjustments for: depreciation, amortisation and impairment 12,956 1,631 financial expense 1,150 902 share of profit of equity-accounted investees (145) (106) equity settled share-based payment expenses 776 133 taxation (1,790) 780 3,886 9,253 increase in trade and other receivables (1,739) (920) decrease (increase) in inventories 651 (575) increase in trade and other payables 3,647 1,241 increase (decrease) in provisions 44 (501) 6,489 8,498 interest paid (929) (720) tax received 546 83 net cash inflow from continuing operating activities 6,106 7,861 net cash outflow from operating activities in discontinued operations (2,222) (884) net cash inflow from operating activities 3,884 6,977 cash flows from investing activities acquisition of property, plant and equipment 13 (719) (1,845) acquisition of subsidiaries, net of cash acquired – (3,285) acquisition of investment – (105) capitalised development expenditure 14 (4,035) (6,355) acquisition of other intangible assets 14 (212) (287) net cash outflow from investing activities in continuing operations (4,966) (11,877) net cash outflow from investing activities in discontinued operations (238) (9,075) net cash outflow from investing activities (5,204) (20,952) cash flows from financing activities proceeds from the issue of share capital (net of expenses) 26 14,271 – proceeds from new loans 20 – 29,520 repayment of borrowings (8,000) (15,754) dividends paid (1,250) (937) net cash inflow from financing activities in continuing operations 5,021 12,829 net cash outflow from financing activities in discontinued operations – (487) net cash inflow from financing activities 5,021 12,342 net increase (decrease) in cash and cash equivalents 3,701 (1,633) cash and cash equivalents at beginning of year 4,240 5,873 cash and cash equivalents at year end 19 7,941 4,240 50 quantum pharma plc annual report and accounts 2017 financial statements 1 accounting policies quantum pharma plc (the ‘company’) is a company incorporated and domiciled in the uk. in respect of acquisitions prior to 1 february 2011, goodwill is included at transition date on the basis of its deemed cost, which represents the amount recorded under uk gaap which was broadly comparable save that only separable intangibles were recognised and goodwill was amortised. subsequent to initial recognition they are measured at amortised cost using the effective interest method, less any impairment losses. subsequent to initial recognition, interest- bearing borrowings are stated at amortised cost using the effective interest method. intangible assets with an indefinite useful life and goodwill are systematically tested for impairment at each balance sheet date. 1.15 post retirement benefits the group makes contributions to employee’s personal pension schemes in line with uk auto-enrolment legislation. new standards awaiting eu endorsement include ifrs 16 ‘leases’ which is effective for annual periods beginning on or after 1 january 2019. the standard replaces ias 17 and will require entities to apply a single lessee accounting model, with lessees recognising right of use assets and lease liabilities on balance sheet for all applicable leases. a reconciliation between adjusted ebitda and profit (loss) before tax is included in the tables below. 60 quantum pharma plc annual report and accounts 2017 financial statements 6 staff numbers and costs the average number of persons employed by the group in continuing and discontinued operations (including directors) during the year, analysed by category, was as follows: 2017 2016 staff numbers sales and commercial 37 35 management and administration 180 152 production 237 233 454 420 2017 £000 2016 £000 staff costs aggregate payroll costs of these persons: wages and salaries 14,679 11,426 social security costs 1,295 1,008 contributions to defined contribution plans (note 22) 422 423 share based payments (note 23) 776 133 deferred consideration accounted for as remuneration (lamda) (note 2) 1,977 1,461 19,149 14,451 7 remuneration of directors 2017 salary/ fees £000 car allowance £000 bonus £000 compensation for loss of office £000 benefit in kind £000 pension contributions £000 total £000 aj scaife 210 9 – 230 1 23 473 mj such 13 7 – 160 1 16 197 j clarke 45 – – – – – 45 s kelly 23 – – – – – 23 c rigg 190 7 125 – 1 19 342 gt murray 5 – – – – – 5 i johnson 17 – – – – – 17 c mills 11 – – – – – 11 j brown 11 – – – – – 11 525 23 125 390 3 58 1,124 2016 salary/ fees £000 car allowance £000 bonus £000 benefit in kind £000 pension contributions £000 total £000 aj scaife 230 9 – 1 23 263 mj such 160 7 – 1 16 184 j clarke 60 – – – – 60 s kelly 30 – – – – 30 480 16 – 2 39 537 directors’ emoluments include emoluments due to the directors of the company. there were no potentially dilutive shares or other instrument that have been excluded from diluted eps because they are antidilutive. the recoverable amount of these cash generating units has been calculated with reference to their value in use. 76 quantum pharma plc annual report and accounts 2017 financial statements note 2017 £000 2016 £000 non-current assets investments 3 735 85 deferred tax assets 4 7 – 742 85 current assets trade and other receivables 5 123,283 121,149 cash and cash equivalents 6 1,565 34 124,848 121,183 total assets 125,590 121,268 current liabilities other interest-bearing loans and borrowings 8 (2,880) (7,880) trade and other payables 7 (738) (172) (3,618) (8,052) non-current liabilities other interest-bearing loans and borrowings 8 (18,080) (20,959) total liabilities (21,698) (29,011) net assets 103,892 92,257 capital and reserves share capital 9 16,912 12,500 share premium 10 74,799 64,940 esop own share reserve 10 (484) (484) retained earnings 10 12,665 15,301 total equity 103,892 92,257 these financial statements were approved by the board of directors on 2 may 2017 and were signed on its behalf by: gt murray director company registered number: 09269818 company balance sheet at 31 january 2017 77 quantum pharma plc annual report and accounts 2017 financial statements company statement of changes in equity share capital £000 share premium £000 esop own share reserve £000 retained earnings £000 total equity £000 balance at 1 february 2016 12,500 64,940 (484) 15,301 92,257 total comprehensive income for the year loss for the year – – – (2,162) (2,162) other comprehensive income – – – – – total comprehensive income for the year – – – (2,162) (2,162) transactions with owners, recorded directly in equity issue of shares 4,412 10,588 – – 15,000 costs charged against share premium – (729) – – (729) equity-settled share based payment transactions – – – 776 776 dividends – – – (1,250) (1,250) total contributions by and distributions to owners 4,412 9,859 – (474) 13,797 balance at 31 january 2017 16,912 74,799 (484) 12,665 103,892 share capital £000 share premium £000 esop own share reserve £000 retained earnings £000 total equity £000 balance at 1 february 2015 12,500 64,940 (484) 16,804 93,760 total comprehensive income for the year loss for the year – – – (569) (569) other comprehensive income – – – – – total comprehensive income for the year – – – (569) (569) transactions with owners, recorded directly in equity equity-settled share based payment transactions – – – 3 3 dividends – – – (937) (937) total contributions by and distributions to owners – – – (934) (934) balance at 31 january 2016 12,500 64,940 (484) 15,301 92,257 78 quantum pharma plc annual report and accounts 2017 financial statements 1 accounting policies the following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company’s financial statements, except as noted below. the accounting policies set out below have, unless otherwise stated, been applied consistently to all periods presented in these financial statements. subsequent to initial recognition they are measured at amortised cost using the effective interest method, less any impairment losses. subsequent to initial recognition, interest- bearing borrowings are stated at amortised cost using the effective interest method, less any impairment losses.